Health Economics›Cervical cancer›Advanced or metastatic disease subsequent lines of therapy

Advanced or metastatic disease subsequent lines of therapy

Cervical cancer · 12 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 4 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Pembrolizumab monotherapy Variant #01	—	R 286 955	14d	~5.8 mo	~15.5 mo	~2	~R 573 911 PFS proxy · indirect	40
Bevacizumab monotherapy Variant #01	—	R 19 082	14d	~20.4 mo	~51.6 mo	~52	~R 992 271 PFS proxy · indirect	3
Topotecan monotherapy Variant #01	—	R 18 138	21d	—	9.0 mo	11	R 199 522 PFS proxy	2
Pemetrexed monotherapy Variant #01	—	R 13 225	21d	—	9.0 mo	4	R 52 900 PFS proxy	2
Cisplatin and Gemcitabine (GC) Variant #01	—	R 3 933	21d	—	~10.3 mo	~6	~R 23 595 PFS proxy · indirect	1
FULV Variant #29	—	R 3 601	14d	~5.6 mo	~13.1 mo	~2	~R 7 201 PFS proxy · indirect	15
Docetaxel monotherapy Variant #02	—	R 2 921	28d	~3.2 mo	~9.5 mo	~9	~R 26 293 PFS proxy · indirect	83
Irinotecan monotherapy Variant #01	—	R 2 716	42d	—	9.0 mo	11	R 29 874 PFS proxy	2
Gemcitabine monotherapy Variant #01	—	R 1 672	21d	—	9.0 mo	7	R 11 705 PFS proxy	2
Vinorelbine monotherapy Variant #01	—	R 458	21d	—	9.0 mo	12	R 5 490 PFS proxy	2
Cemiplimab monotherapy Variant #01 Partial	—	—	21d	—	11.9 mo	48	—	2
Tisotumab vedotin monotherapy Variant #01 Partial	—	—	21d	—	11.5 mo	2	—	1

12 of 12 regimens shown